Kiker Wealth Management LLC Makes New $1.23 Million Investment in Haemonetics Co. (NYSE:HAE)

Kiker Wealth Management LLC bought a new stake in Haemonetics Co. (NYSE:HAE) in the fourth quarter, HoldingsChannel.com reports. The institutional investor bought 15,802 shares of the medical instruments supplier’s stock, valued at approximately $1,234,000. Haemonetics makes up approximately 1.0% of Kiker Wealth Management LLC’s holdings, making the stock its 24th biggest holding.

Several other institutional investors and hedge funds have also made changes to their positions in the business. Whittier Trust Co. acquired a new position in shares of Haemonetics in the fourth quarter worth $62,000. Xponance Inc. increased its position in Haemonetics by 5.9% during the fourth quarter. Xponance Inc. now owns 7,246 shares of the medical instruments supplier’s stock worth $566,000 after purchasing an additional 404 shares during the last quarter. Boston Partners raised its position in shares of Haemonetics by 27.5% in the 4th quarter. Boston Partners now owns 536,262 shares of the medical instruments supplier’s stock worth $41,485,000 after buying an additional 115,506 shares during the period. Intech Investment Management LLC lifted its stake in shares of Haemonetics by 107.5% in the 4th quarter. Intech Investment Management LLC now owns 46,338 shares of the medical instruments supplier’s stock valued at $3,618,000 after purchasing an additional 24,009 shares in the last quarter. Finally, Thrivent Financial for Lutherans grew its stake in Haemonetics by 14.9% during the fourth quarter. Thrivent Financial for Lutherans now owns 1,264,294 shares of the medical instruments supplier’s stock worth $98,716,000 after buying an additional 164,111 shares during the period. 99.67% of the stock is currently owned by hedge funds and other institutional investors.

Haemonetics Trading Down 1.5 %

Shares of HAE opened at $64.28 on Friday. The company has a current ratio of 3.97, a quick ratio of 2.55 and a debt-to-equity ratio of 1.35. The stock has a 50 day simple moving average of $67.54 and a 200-day simple moving average of $75.11. Haemonetics Co. has a 1 year low of $58.80 and a 1 year high of $97.97. The stock has a market cap of $3.23 billion, a PE ratio of 25.31, a PEG ratio of 1.11 and a beta of 0.43.

Haemonetics (NYSE:HAE) last released its quarterly earnings results on Thursday, February 6th. The medical instruments supplier reported $1.19 EPS for the quarter, missing the consensus estimate of $1.20 by ($0.01). Haemonetics had a net margin of 9.47% and a return on equity of 23.66%. On average, sell-side analysts predict that Haemonetics Co. will post 4.55 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages recently commented on HAE. StockNews.com downgraded Haemonetics from a “buy” rating to a “hold” rating in a report on Saturday, February 15th. JPMorgan Chase & Co. initiated coverage on Haemonetics in a research report on Friday, December 6th. They set an “overweight” rating and a $116.00 price target on the stock. Raymond James reissued a “strong-buy” rating and issued a $115.00 target price (down previously from $120.00) on shares of Haemonetics in a report on Friday, February 7th. JMP Securities lowered their price target on shares of Haemonetics from $125.00 to $100.00 and set a “market outperform” rating for the company in a research report on Friday, February 7th. Finally, Needham & Company LLC lowered their target price on Haemonetics from $108.00 to $104.00 and set a “buy” rating on the stock in a research report on Tuesday. One analyst has rated the stock with a sell rating, two have issued a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $101.22.

Haemonetics Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.